<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00854971</url>
  </required_header>
  <id_info>
    <org_study_id>BX-TK-002</org_study_id>
    <nct_id>NCT00854971</nct_id>
  </id_info>
  <brief_title>Efficacy Study of TKcell in Advanced Colorectal Cancer</brief_title>
  <official_title>Evaluating the Safety and Efficacy of Combination Therapy With FOLFOX-4 and TKcell Therapy Versus FOLFOX-4 Alone in Patients With Recurrent, Unresectable and Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Binex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Binex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy of NKCell in colorectal cancer
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine response rate</measure>
    <time_frame>within study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine safety of combination,time to treatment failure, overall survival time</measure>
    <time_frame>within study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oxaliplatin infusion (85mg/m2) on days 1 and 15 (every 2 weeks) 5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16 LV infusions (200 mg/m2) on days 1, 2, 15 and 16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOX-4 regimen + Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TKCell</intervention_name>
    <description>Biological/Vaccine: TKCell</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>NKCell</other_name>
    <other_name>FOLFOX-4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Diagnosis of histologically confirmed adenocarcinoma of the colorectal

          -  ECOG performance status of 0 - 2

          -  At least one definite measurable lesion(s): ≥ 1 cm on spiral CT scan or ≥2cm in
             physical examination

          -  Adequate liver, renal, bone marrow functions as evidence by the following;

          -  Absolute neutrophil count &gt; 1.5 x 109/L; platelets &gt; 7.5 x 109/L; Bilirubin less than
             2 mg/dL ASAT and/or ALAT &lt; 5 UNL; serum creatinine ≤ 2 ULN

          -  Minimum life expectancy of 12 weeks

          -  Effective contraception for both male and female subjects if the risk of conception
             exists

        Exclusion Criteria:

          -  Brain metastasis and/or leptomeningeal disease (known or suspected)

          -  Previous chemotherapy for gastric cancer except adjuvant treatment with progression of
             disease documented &gt; 6 months after end of adjuvant treatment.

          -  Previous oxaliplatin-based chemotherapy

          -  Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to
             randomization and chemotherapy

          -  HIV antibody (+), Chronic hepatitis

          -  Uncontrolled infection

          -  Concurrent or previous chronic systemic immune therapy, targeted therapy, hormonal
             therapy not indicated in the study protocol except for contraception

          -  Clinically relevant coronary artery disease, history of myocardial infarction, high
             risk of uncontrolled arrhythmia

          -  Known hypersensitivity reaction to any of the components of the treatment.

          -  Pregnancy (absence to be confirmed by ß-hCG test) or lactation period

          -  Participation in another clinical study within the 30 days before randomization

          -  Significant disease which, in the investigator's opinion, would exclude the subject
             from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seok-Goo Cho, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <state>Banpo-dong</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.bi-nex.com/</url>
    <description>(Click here for more information about this study.)</description>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2009</study_first_submitted>
  <study_first_submitted_qc>March 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2009</study_first_posted>
  <last_update_submitted>May 15, 2009</last_update_submitted>
  <last_update_submitted_qc>May 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Park, Eun-Jin / Research institute</name_title>
    <organization>CRM(clinical research manager)</organization>
  </responsible_party>
  <keyword>NKCell</keyword>
  <keyword>FOLFOX-4</keyword>
  <keyword>advanced or unresectable colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

